A New Prostatic Stent for the Treatment of Benign Prostatic Hyperplasia in High&amp;ndash;Risk Patients

Traxer, O.; Anidjar, Maurice; Gaudez, F.; Saporta, François; Daudon, Michel; Cortesse, A.; Desgrandchamps, F.; Cussenot, Olivier; Teillac, P.; Duc, A. Le

doi:10.1159/000020293

Cited by 12 publications

(9 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Relatively higher complication rates associated with their use limit their utility as a long-term durable option in BPH management. Further large-scale studies are required to definitively establish the efficacy of these stents 24, 25, 26…”

Section: Mechanicalmentioning

confidence: 99%

Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies

Christidis

McGrath

Perera

et al. 2017

Prostate International

View full text Add to dashboard Cite

The prevalence of benign prostatic hypertrophy (BPH) causing bothersome lower urinary tract symptoms increases with our ageing population. Treatment of BPH traditionally begins with medical therapy and surgical intervention is then considered for those whose symptoms progress despite treatment. Minimally invasive surgical therapies have been developed as an intermediary in the treatment of BPH with the aim of decreasing the invasiveness of interventions. These therapies also aim to reduce morbidity and dysfunction related to invasive surgical procedures.Multiple treatment options exist in this group including mechanical and thermo-ablative strategies. Emerging therapies utilizing differing technologies range from the established to the experimental. We review the current literature related to these minimally invasive therapies and the evidence of their effectiveness in treating BPH.The role of minimally invasive surgical therapies in the treatment of BPH is still yet to be strongly defined. Given the experimental nature of many of the modalities, further study is required prior to their recommendation as alternatives to invasive surgical therapy. More mature evidence is required for the analysis of durability of effect of these therapies to make robust conclusions of their effectiveness.

show abstract

Section: Mechanicalmentioning

confidence: 99%

Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies

Christidis

McGrath

Perera

et al. 2017

Prostate International

View full text Add to dashboard Cite

show abstract

“…He demonstrated that hydrogel-coated stents displayed faster encrustation than others, requiring special surveillance and frequent replacement [36][37][38][39][40]. Other researches were performed with cardiologists and vascular surgeons on bio-prosthesis and aortic valves [41,42].…”

Section: Endoprosthesis Encrustationsmentioning

confidence: 99%

A great contributor to the French urological science: Michel Daudon

Doré

2014

Comptes Rendus. Chimie

View full text Add to dashboard Cite

The 40 years of Michel Daudon's working life in the field of urolithiasis are difficult to sum up in a few lines. His knowledge, expertise and publications in the fields of biology, chemistry, nephrology, and eventually urology have contributed to make him a national and international recognized researcher in the understanding of the complex mechanisms of urolithogenesis. His great collaboration with the community of nephrologists, kidney physiologists, biologists, and urologists, seniors or in training, has widely contributed to improve modern and complete treatments of urolithiasis, which is at the origin of complicated urinary stones causing severe consequences on renal function and true public health problems. His hard working, his willingness, and the clarity of his presentations contributed to make him a national and international recognized lecturer in France and North Africa, where he created a network connecting laboratories with clinicians. Always looking forward in his scientific field, he has established links with approved research teams, making them interested in working on urolithiasis, even though research on urolithiasis disease seems to be less important than research on cancer. ß 2014 Acadé mie des sciences. Published by Elsevier Masson SAS. All rights reserved. R É S U M É La vie de travail de Michel Daudon ne peut se ré sumer en quelques lignes. Ses compé tences en clinique, en biologie et en biochimie ont fait de lui un acteur reconnu sur le plan national et international dans la compré hension des mé canismes de la lithogenè se urinaire, source de calculs souvent complexes aux consé quences parfois graves. Il a largement contribué à la prise en charge moderne et complè te de la lithiase urinaire, en permettant aux né phrologues cliniciens et physiologistes, aux biologistes, mais aussi aux urologues sé niors et/ou en formation, de mieux cerner la complexité des calculs ré naux et leurs consé quences sur la fonction ré nale ayant un impact en santé publique. Son travail incessant, sa disponibilité et la clarté de ses exposé s ont contribué à le faire reconnaître comme un enseignant recherché par la communauté urologique aussi bien en France que dans les pays é trangers, notamment en Afrique du Nord, en cré ant des ré seaux de

show abstract

“…Prostatic stents have been used either temporarily in patients with retention or permanently in patients who are poor surgical candidates [1,2,3,4,5,6,7,8,9,10,11,12,13]. Up to 10-15% of patients are unsuitable for surgery because of severe co-morbidities [4].…”

Section: Introductionmentioning

confidence: 99%

First Experiences with the Spanner™ Temporary Prostatic Stent for Prostatic Urethral Obstruction

Goh

Kastner²,

Khan³

et al. 2013

Urol Int

View full text Add to dashboard Cite

Objectives: To assess the ease of insertion and removal of a temporary prostatic stent (the Spanner™) following the use of a prostatic urethral measuring device (the Surveyor™). Patients and Methods: Patients with bladder outflow obstruction or urinary retention awaiting definitive surgery were fully consented. Data were collected pre- and post-insertion and patients followed-up until definitively treated. Results: 16 patients had the Spanner inserted following use of the Surveyor. All insertions were uncomplicated. 14 patients were able to void satisfactorily immediately post-insertion with a mean Q_max of 15.0 ml/s and post-void residual of 51.3 ml. No symptomatic infection was reported. The stents stayed in situ for a median of 10 days. 12 stents were removed prematurely due to severe symptoms or retention. A total of 12 stents had to be removed endoscopically. Conclusions: The Spanner is easy to insert. Stent removal via the retrieval suture has been difficult necessitating the use of endoscopy in the majority of cases. Possible causes of stent failure include underestimation of the prostatic urethral length by the Surveyor leading to obstruction by apical prostatic tissue, excessive suture length between the stent and distal anchor permitting proximal migration or inadequate suture length leading to urinary incontinence. Further design modifications are suggested.

show abstract

A New Prostatic Stent for the Treatment of Benign Prostatic Hyperplasia in High–Risk Patients

Cited by 12 publications

References 39 publications

Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies

Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies

A great contributor to the French urological science: Michel Daudon

First Experiences with the Spanner™ Temporary Prostatic Stent for Prostatic Urethral Obstruction

Contact Info

Product

Resources

About